Research Group Lickert

Stem and Progenitor Cells in Pancreas Development, Regeneration and Drug Screening


The lack or dysfunction of insulin-producing ß-cells is the cause of type I or type II diabetes, respectively. The primary objective of the Institute of Diabetes and Regeneration Research (IDR) at the Helmholtz Zentrum München is to develop regenerative therapeutic approaches to treat diabetes mellitus - complementary and alternative to the classical immunological and metabolic therapy strategies.

In vitro generation of ß-cells from pluripotent stem cells for cell-replacement therapy or triggering endogenous mechanisms of ß-cell repair have great potential in the field of regenerative medicine. Both approaches rely on a thorough understanding of ß-cell development and homeostasis in pre-clinical models.

Therefore the aim is to improve current strategies for functional ß-cell production in vitro with the ultimate goal to provide alternative sources of ß-cells for therapy. Additionally, we analyze and characterize the embryonic and adult pancreatic progenitor cells to understand ß-cell development, homeostasis and function for in vivoregeneration.


Research Aims:

  • Identification of novel signals and factors involved in pancreas development
  • Progenitor cells and mechanisms involved in pancreas regeneration
  • Embryonic stem cell differentiation into ß-cells for cell-replacement therapy Identification of novel small molecules with therapeutic potential able to trigger ß-cell repair or endocrine-lineage differentiation

   
   

We use cookies to improve your experience on our Website. We need cookies to continuously improve the services, to enable certain features and when embedding services or content of third parties, such as video player. By using our website, you agree to the use of cookies. We use different types of cookies. You can personalize your cookie settings here:

Show detail settings
Please find more information in our privacy statement.

There you may also change your settings later.